Efficacy of quinagolide in resistance to ergot dopamine agonists: Results of a multicenter study

Annales d'Endocrinologie

Volumn 61, Issue 5, 2000, Pages 411-417

  Rohmer, V ^a   Freneau, E ^a   Morange, I ^a   Simonetta, C ^a  

^a Service de medecine C   (France)

Author keywords

Anti tumoral effect; Prolactin adenoma; Quinagolide; Resistant prolactinomas

Indexed keywords

BROMOCRIPTINE; LISURIDE; PROLACTIN; QUINAGOLIDE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; NAUSEA; PROLACTIN BLOOD LEVEL; PROLACTIN SECRETING CELL; PROLACTINOMA; TUMOR REGRESSION; TUMOR VOLUME; VOMITING;

AMINOQUINOLINES; BROMOCRIPTINE; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES;

EID: 0033694848     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Le traitement des protactinomes parun nouvel agoniste dopaminergique (le CV 205-502): Resultats chez 48 patients
2. Quinagolide (Norprolac®): Novel non-ergot prolactin inhibitor
3. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine
4. Prolactinomas resisrant to standard dopamine agonists respond to chronic cabergoline treatment
5. Specifieffect of CV 205-502, a potent non-ergot dopamine agonist, during a combined anterior pituitary function test
6. Use of quinagolide in hyperprolactinaemic patients who are intolerant and/or resistant to bromocriptine
7. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine
8. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study
9. Prolactinomas resistant to bromocriptine: Long term efficacy of quinagolide and outcome of pregnancy
10. Resistance to bromocriptine in prolactinomas
11. Effect of CV205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine
12. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502
13. Quinagolide efficacy and tolerability in hyperprolactinemic patients who are resistant to or intolerant of bromocriptine